Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Grant of share options
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, have each been granted an award of restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company ("Ordinary Shares") under the existing Tissue Regenix Share Incentive Plan.
Daniel Lee has been awarded 27,560,776 RSUs and David Cocke has been awarded 21,383,361 RSUs, where each RSU that vests shall represent the right to receive payment of one Ordinary Share. The exercise price of the RSUs is 0.1p per Ordinary Share. The RSUs are subject to continued service over a period of three years and satisfaction of customary performance conditions relating to growth in total shareholder return, annual revenue targets, annual profitability targets and personal performance targets.
Following the grant of these options, Daniel Lee and David Cocke hold options over a total of 55,882,379 and 36,032,466 RSUs respectively representing 0.8% and 0.5% of the current issued share capital respectively.
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ('MAR'). Upon the publication of this announcement via Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.
For more information:
| Tissue Regenix Group plc David Cocke, Chief Financial Officer | Via Walbrook PR |
|
|
|
| Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Nick Harland | Tel: +44(0)20 7710 7600
|
| Walbrook PR Ltd Alice Woodings / Lianne Applegarth | Tel: +44 (0)20 7933 8780 TissueRegenix@walbrookpr.com |
|
|
|
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.
| 1
| Details of the person discharging managerial responsibilities / person closely associated | |
| a)
| Name | Daniel Lee |
| 2
| Reason for the notification | |
| a)
| Position/status
| CEO |
| b)
| Initial notification /Amendment
| Initial notification |
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a)
| Name
| Tissue Regenix Group plc |
| b)
| LEI | 213800PNOD5UHQUFJI36 |
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a)
| Description of the financial instrument, type of instrument
| Restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company of 0.1p |
| b) | Identification code
| GB00B5SGVL29 |
| c)
| Nature of the transaction
| Issue of options |
| d)
| Price(s) and volume(s) | Volume(s): 27,560,776 RSUs Price: 0.1 pence per RSU |
| d)
| Aggregated information - Aggregated volume - Price |
27,560,776 £27,560.78 |
| e)
| Date of the transactions | 7 April 2022 |
| f)
| Place of the transaction | Outside of a trading venue |
| 1
| Details of the person discharging managerial responsibilities / person closely associated | |
| a)
| Name | David Cocke |
| 2
| Reason for the notification | |
| a)
| Position/status
| CFO |
| b)
| Initial notification /Amendment
| Initial notification |
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a)
| Name
| Tissue Regenix Group plc |
| b)
| LEI | 213800PNOD5UHQUFJI36 |
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a)
| Description of the financial instrument, type of instrument
| Restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company of 0.1p |
| b) | Identification code
| GB00B5SGVL29 |
| c)
| Nature of the transaction
| Issue of options |
| d)
| Price(s) and volume(s) | Volume(s): 21,383,361 RSUs Price: 0.1 pence per RSU |
| d)
| Aggregated information - Aggregated volume - Price |
21,383,361 £21,383.36 |
| e)
| Date of the transactions | 7 April 2022
|
| f)
| Place of the transaction | Outside of a trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
